证券代码：300326 证券简称：凯利泰 公告编号：2024-016 上海凯利泰医疗科技股份有限公司 关于向合营公司提供财务资助暨关联交易的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1、上海凯利泰医疗科技股份有限公司(以下简称"公司")拟向合营公司上海意 久泰医疗科技有限公司(以下简称"上海意久泰")提供借款人民币 7,140,000 元， 借款年利率为 4.20%，借款期限为五年，自上海意久泰收到首笔借款之日起起算， 上海意久泰应于借款到期日之时向公司支付借款的全部本金及利息。 2、上海意久泰其他股东 Tecres S.p.A.同意按持股比例等比例向其提供借款 人民币 6,860,000 元，借款年利率为 4.20%，借款期限为五年，自上海意久泰收 到首笔借款之日起起算，上海意久泰应于借款到期日之时向 Tecres S.p.A.支付借 款的全部本金及利息。 3、本次财务资助暨关联交易事项已经公司第五届董事会第十四次会议和第 五届监事会第十四次会议审议通过，需提交公司股东大会审议。 4、本次财务资助暨关联交易被资助对象为公司的合营公 ...

大华会计师事务所（特殊普通合伙）（以下简称"大华所"）成立于 1985 年，2012 年 2 月由大华会计师事务所有限公司转制为特殊普通合伙。注册地址 在北京市海淀区西四环中路 16 号院 7 号楼 1101，首席合伙人为梁春。截至 2023 年 12 月 31 日合伙人 270 人，注册会计师 1471 人（其中：签署过证券服务业务 审计报告的注册会计师1141人）。大华所在国内重要城市设立了30家分支机构。 2022 年度业务总收入 33.27 亿元、审计业务收入 30.74 亿元、证券业务收入 13.89 亿元。 （二）聘任会计师事务所履行的程序 公司于 2023 年 4 月 20 日召开第五届董事会第七次会议，审议通过了《关于 公司续聘财务审计机构的议案》，后该议案于 2023 年 5 月 24 日经 2023 年年度 股东大会审议通过。公司独立童事对上述议案发表了事前认可和同意的独立意见。 二、审计委员会对会计师事务所监督情况 上海凯利泰医疗科技股份有限公司董事会审计委员会 对会计师事务所 2023 年度履行监督职责情况报告 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司 治理准 ...

上海凯利泰医疗科技股份有限公司 控股股东及其他关联方资金占用情况的 专项说明 大华核字[2024]0011009727 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified Public Accountants（Special General Partnership） 上海凯利泰医疗科技股份有限公司 大华会计师事务所（特殊普通合伙） 北京市海淀区西四环中路 16 号院 7 号楼 12 层 [100039] 电话：86 (10) 5835 0011 传真：86 (10) 5835 0006 www.dahua-cpa.com 控股股东及其他关联方 资金占用情况的专项说明 大华核字[2024] 0011009727号 上海凯利泰医疗科技股份有限公司全体股东： 根据中国证券监督管理委员会发布的《上市公司监管指引第 8 号 ——上市公司资金往来、对外担保的监管要求》（证监会公告[2022]26 号）和深圳证券交易所《深圳证券交易所创业板上市公司自律监管指 南第 1 号——业务办理（2023 年 2 月修订）》的规定，就凯利泰编制 的 2023 年度非经营性资金占用及其他关 ...

上海凯利泰医疗科技股份有限公司 审计报告 大华审字[2024]0011002303 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified Public Accountants（Special General Partnership） ［右键单击上一行首，选择更新域键入公司名称的全称］ ［右键单击上一行首，选择更新域键入公司名称的简称］ 上海凯利泰医疗科技股份有限公司 审计报告及财务报表 （2023 年 1 月 1 日至 2023 年 12 月 31 日止） | | 目 | 录 | 页 次 | | --- | --- | --- | --- | | 一、 | 审计报告 | | 1-7 | | 二、 | 已审财务报表 | | | | | 合并资产负债表 | | 1-2 | | | 合并利润表 | | 3 | | | 合并现金流量表 | | 4 | | | 合并股东权益变动表 | | 5-6 | | | 母公司资产负债表 | | 7-8 | | | 母公司利润表 | | 9 | | | 母公司现金流量表 | | 10 | | | 母公司股东权益变动表 | | 11-12 ...

Financial Performance - In 2023, the company achieved operating revenue of RMB 956.26 million, a decrease of 17.99% compared to the previous year[6]. - The net profit attributable to shareholders was RMB 112.54 million, an increase of 628.78% year-on-year[6]. - The decline in revenue was primarily due to the implementation of the national volume-based procurement policy affecting the sales prices of orthopedic products[6]. - The company fully recognized goodwill impairment of RMB 197.99 million from the acquisition of Aideer in the previous year, contributing to the significant profit increase in 2023[6]. - The report indicates that the overall operating performance showed substantial changes compared to the same period last year[6]. - The company's operating revenue for 2023 was ¥956,259,537.45, a decrease of 17.99% compared to ¥1,166,042,082.06 in 2022[23]. - Net profit attributable to shareholders was ¥112,537,303.89, a significant increase of 628.78% from a loss of ¥21,282,494.18 in 2022[23]. - The net profit after deducting non-recurring gains and losses was ¥61,648,763.58, up 327.50% from a loss of ¥27,098,445.37 in 2022[23]. - Cash flow from operating activities was ¥274,260,691.58, representing a 15.84% increase from ¥236,756,963.51 in 2022[23]. - Basic and diluted earnings per share were both ¥0.1570, a 630.41% increase from a loss of ¥0.0296 in 2022[23]. - Total assets at the end of 2023 were ¥3,354,004,114.33, a decrease of 1.70% from ¥3,412,148,611.26 at the end of 2022[23]. - Net assets attributable to shareholders increased by 4.39% to ¥2,859,842,987.33 from ¥2,739,569,604.96 in 2022[23]. - The company reported a quarterly revenue of ¥294,401,832.83 in Q1 2023, which decreased to ¥213,839,891.49 in Q3 2023[26]. - The company experienced a net profit of ¥74,900,497.03 in Q1 2023, which turned into a loss of ¥16,629,549.62 in Q4 2023[26]. - In 2023, the company reported a total profit of 50,888,540.31, a significant increase from 5,815,951.19 in 2022, marking a year-over-year growth of approximately 775.5%[31]. - The company received government subsidies amounting to 23,359,830.49 in 2023, compared to 22,158,373.72 in 2022, reflecting a growth of about 5.4%[31]. Business Operations and Strategy - The company plans to continue monitoring the impact of procurement policies on its business operations and adjust strategies accordingly[7]. - The company is undergoing changes in accounting policies due to new regulations effective from January 1, 2022, impacting financial reporting[24]. - The company is committed to continuous development in minimally invasive orthopedic medical devices, covering multiple product lines including spinal and trauma products[35]. - The company is navigating regulatory challenges and opportunities presented by recent healthcare reforms, which are reshaping the competitive landscape in the orthopedic medical device sector[36]. - The company plans to enhance its product innovation in orthopedics, focusing on new materials and technologies, while also expanding its business lines to mitigate the negative impacts of procurement policies[42]. - The company is actively developing a diversified medical device distribution service platform to improve its market share and influence in the medical device sales sector[48]. - The company aims to implement a "one invoice system" sales model targeting large hospitals, in line with national medical reform policies[48]. - The company is focusing on innovation in orthopedic products and expanding its international market presence[62]. - The company is implementing cost control measures to enhance profitability, including reducing labor costs and optimizing production processes[62]. - The company is expanding its product specifications to meet market demands, enhancing competitiveness in the orthopedic and neurosurgical product lines[92]. - The company plans to pursue capital expansion strategies through acquisitions and investments in related medical device companies, particularly in the minimally invasive orthopedic field[135]. - The company will enhance its multi-brand strategy by integrating existing sales channels and strengthening collaboration across product lines, aiming to establish a diverse sales network targeting hospitals[136]. - The company plans to accelerate the internationalization strategy, focusing on the PKP/PVP and Elliquence product lines, with dedicated management roles for foreign trade development in various countries[137]. Market and Industry Trends - The orthopedic implant medical device industry is experiencing rapid growth, with domestic companies benefiting from market expansion and import substitution[36]. - The average price reduction in orthopedic trauma medical consumables during centralized procurement reached 88.65%, significantly impacting industry expectations[37]. - The average price drop for selected orthopedic spinal consumables in centralized procurement was 84%, effective from January 2023[39]. - The national centralized procurement for high-value medical consumables, including artificial crystals and sports medicine supplies, resulted in an average price drop of 74% for sports medicine consumables[40]. - The implementation of bulk procurement policies in the orthopedic consumables sector is expected to significantly reduce patient financial burdens and standardize medical practices, leading to the gradual elimination of smaller, less innovative companies[41]. - The medical device industry is facing challenges due to policies aimed at controlling medical insurance costs, which may limit the growth of medical device expenses in healthcare institutions[130]. - The implementation of volume-based procurement policies is expected to increase pressure on pharmaceutical companies while also improving the quality and competitiveness of the medical industry[132]. - Increased competition in the orthopedic market is anticipated, necessitating timely product innovation to maintain profit margins[146]. Research and Development - R&D investment totaled 60.35 million yuan, a decrease of 8.30 million yuan or 12.09% year-on-year, with R&D expenditure accounting for 6.31% of current revenue, an increase of 0.42 percentage points[69]. - The company authorized 37 patents during the reporting period, including 5 invention patents, emphasizing its commitment to intellectual property management[69]. - The number of R&D personnel increased to 104 in 2023, a rise of 25.30% compared to 83 in 2022[93]. - The proportion of R&D personnel with master's degrees increased by 180.00%, from 5 in 2022 to 14 in 2023[93]. - The company is focusing on optimizing its surgical instrument packages based on clinical feedback, which is expected to improve operational efficiency[93]. - The company aims to strengthen its research and development capabilities, focusing on minimally invasive orthopedic surgical products to maintain a competitive edge in the market[134]. Acquisitions and Investments - The company has successfully integrated its product lines and sales channels following the acquisition of Aideer, optimizing its offerings in orthopedic implants and surgical instruments[46]. - The acquisition of Elliquence, LLC has allowed the company to expand into new business areas, particularly in surgical energy platforms and high-value consumables, enhancing its market presence[47]. - The company acquired a 56% stake in Jienuo Medical, enhancing its market competitiveness and operational efficiency in the medical sterilization service sector[50]. - The company completed the acquisition of 100% equity in Elliquence, LLC for approximately $77,152,000 (about ¥49,500 million) as part of its internationalization strategy[1]. - The company completed the acquisition of 100% equity in Jiangsu Aidi Medical Technology Co., Ltd., enhancing its market position[120]. - The registered capital of Jiangsu Aidi was increased from 60 million yuan to 110 million yuan, reflecting the company's commitment to growth[121]. - The company invested 15 million yuan in the Shanghai Hongsheng Houde Private Equity Investment Fund and 10 million yuan in Dongzhi Medical, among other investments, to enhance its industry presence[72]. Governance and Compliance - The financial report was confirmed to be accurate and complete by the board of directors and management, with no significant discrepancies noted[4]. - The company has established independent financial, operational, and personnel systems, ensuring no interference from existing shareholders[183]. - The company has implemented information disclosure management systems to ensure transparency and timely communication with stakeholders[170]. - The company respects and protects the rights of all stakeholders, promoting sustainable and healthy development[171]. - The company has conducted 1 annual and 1 extraordinary shareholders' meeting during the reporting period, ensuring compliance with legal requirements[163]. - The company maintains strict compliance with the "Investor Relations Management System" to ensure effective communication with investors[172]. - The company has established a performance evaluation and incentive system linking management compensation to business performance[168]. Future Outlook - Future outlook includes a projected revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies[190]. - The company is investing 368.4 million in research and development for new technologies and products in the upcoming year[191]. - Market expansion efforts are focused on increasing presence in Southeast Asia, with a target of capturing an additional 10% market share by 2025[192]. - New product lines are expected to launch in Q3 2024, which are anticipated to contribute an additional 5% to overall revenue[194]. - The company has set a goal to reduce operational costs by 10% through efficiency improvements and technology integration[197]. - The company aims to enhance customer engagement through digital platforms, expecting a 30% increase in online interactions[200]. - Future guidance indicates a focus on sustainability initiatives, with a commitment to reduce carbon emissions by 20% over the next five years[200].

2023 年度独立董事述职报告（郑卫茂） 2023 年度，本人郑卫茂作为上海凯利泰医疗科技股份有限公司（以下简称 "公司"）的独立董事，在职期间严格按照《深圳证券交易所创业板股票上市规则》、 《上市公司自律监管指引第 2 号——创业板上市公司规范运作》、《上市公司独立 董事管理办法》及《公司章程》等规定，审慎、勤勉、独立的履行职责，积极出 席相关会议，认真审议董事会各项议案，严格审核公司提交董事会的相关事项， 对公司重大事项发表了独立意见；同时作为审计委员会主任委员，发挥专业优势， 为公司的内部审计、内部控制等方面的工作提出了意见和建议，充分发挥独立董 事的独立性和专业性作用，维护公司股东特别是中小股东的合法权益，促进了公 司的规范运作。现就本人 2023 年度履行职责情况汇报如下： 一、 独立董事的基本情况介绍 报告期内，本人任职符合《上市公司独立董事管理办法》第六条规定的独立 性要求，不存在影响独立性的情况。本人履历如下： 郑卫茂先生，1963 年 8 月出生，现任公司独立董事，中国国籍，无境外永久 居留权。上海海事大学管理学硕士，注册会计师非执业会员，具备独立董事资格 证书。1985 年 7 月毕业于山 ...

证券代码：300326 证券简称：凯利泰 公告编号：2024-018 上海凯利泰医疗科技股份有限公司 关于使用闲置自有资金理财的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 上海凯利泰医疗科技股份有限公司(以下简称"公司")于 2024 年 4 月 18 日召开第五届董事会第十四次会议，于 2024 年 4 月 19 日召开第五届监事会第十 四次会议，审议通过了《关于使用闲置自有资金理财的议案》，为提高资金使用 效率、增加公司收益，公司拟使用部分闲置自有资金进行理财，具体计划如下: 一、投资概况 1、资金额度 2、资金来源 公司用于理财的资金为自有资金，资金来源合法合规。 3、投资产品品种 公司将遵守审慎投资原则，严格筛选发行主体，选择安全性高、流动性好的 中低风险理财产品（包括但不限于结构性存款、协定存款、通知存款、定期存款、 大额存单、收益凭证等），理财产品的受托方包括但不限于银行、证券公司等金 融机构。 4、投资期限及实施方式 本次授权期限为公司董事会审议通过之日起 12 个月内，在额度范围内公司 董事会授权董事长行使该项投资决策权并签署相关合同 ...

上海凯利泰医疗科技股份有限公司 2023 年度内部控制自我评价报告 上海凯利泰医疗科技股份有限公司（以下简称"公司"）为了有效地开展公司经营活动， 控制经营风险，保护公司及投资者的合法权益，按照《中华人民共和国公司法》（以下简称《公" 司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《企业内部控制基本规范》、 《深圳证券交易所创业板上市公司规范运作指引》等有关法律法规和规范性文件的要求，结 合自身经营管理特点和实际情况，不断完善公司治理，强化内控建设，有效防范了经营决策 及管理风险，保证公司规范运作和健康发展，保护投资者的合法权益。公司董事会对 2023 年度公司内部控制的规范性、完整性以及实施的有效性进行全面评估。 一、董事会对内部控制自我评价报告真实性的声明 建立健全和有效实施内部控制，评价其有效性，并如实披露内部控制评价报告是公司董 事会的责任。监事会对董事会建立和实施内部控制进行监督。管理层负责组织领导公司内部 控制的日常运行。本公司董事会及全体董事保证本报告内容不存在任何虚假记载、误导性陈 述或重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 公司内部控制的目标是合理 ...

2023 年度独立董事述职报告（戴雪光） 2023 年度，本人作为上海凯利泰医疗科技股份有限公司（以下简称"公司"） 的独立董事，在职期间严格按照《中华人民共和国公司法》、《上市公司独立董事 规则》、《深圳证券交易所创业板股票上市规则》《上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》、《上市公司独立董事管理办法》及《公司章程》 等规定，在工作中，诚实、勤勉、独立地认真行使独立董事的职责，积极出席相 关会议，审议董事会各项议案，严格审核公司提交董事会的相关事项，全面关注 公司的发展状况，维护公司整体利益和全体股东尤其是中小股东的合法权益。现 就本人 2023 年度履行职责工作情况汇报如下： 一、 独立董事的基本情况介绍 报告期内，本人任职符合《上市公司独立董事管理办法》第六条规定的独立 性要求，不存在影响独立性的情况。本人履历如下： 戴雪光先生，1976 年 11 月出生，中国国籍，无境外永久居留权，硕士研究 生学历，律师。2009 年至 2016 年 2 月，任职于北京市中银（上海）律师事务所， 历任律师、合伙人。2016 年 2 月至 2023 年 9 月，任职于北京金诚同达（上海） 律师事务 ...

股票代码：300326 股票简称：凯利泰 上海凯利泰医疗科技股份有限公司 2023 年财务决算报告 上海凯利泰医疗科技股份有限公司 二 0 二三年度财务决算报告 上海凯利泰医疗科技股份有限公司 2023 年财务决算报告 一、2023 年度公司整体经营情况 披露日期：二○二四年四月二十二日 1 2023 年度，公司实现营业收入 95,625.95 万元，较上年度下降 17.99%，营业利润和利润总额分别为 14,007.55 万元和 13,357.37 万元，分别较上年同期增长 143273.08%和 6001.20%；归属于上市公司股东的 净利润 11,253.73 万元，扣除非经常损益后归属于上市公司股东的净利润 6,164.88 万元，分别较上年同 期增长 628.78%和 327.50%。 报告期内，公司整体经营业绩较上年同期有较大幅度变动，主要受以下因素综合影响： 1、报告期内，国家脊柱类高值耗材带量采购政策在各个地区逐步落地实施，公司的各主要骨科业务 如椎体成形、脊柱微创、射频消融、创伤类产品均受到带量采购政策的影响，集采范围内各类产品的销售 价格大幅下降，由此导致公司该些业务板块的营业收入及毛利率 ...